Abbas El-Sayed Abbas, MD
Abbas El-Sayed Abbas has been appointed Thoracic Surgeon-in-Chief and Surgical Director of Lung Cancer, Thoracic Malignancy and Foregut Disease Programs for Temple University Health System, Philadelphia, US. Dr. Abbas will continue […] Read more
National Comprehensive Cancer Network NSCLC Guideline Updates for 2016: Non-Small Cell Lung Cancer
By Erik J. MacLaren, PhD The table at right lists key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as of February 2016. These guidelines are not […] Read more
By Luis E. Raez, MD, FACP, FCCP The International Association for the Study of Lung Cancer (IASLC) and the Peruvian Oncology Research Group (GECO) organized and hosted the “Best of […] Read more
By Prof. Brigit Toebes, PhD, and Willem Bantema, MSc, in collaboration with Wanda de Kanter, MD Critics have warned that Dutch legislation and policy increasingly lag behind that of other […] Read more
By Nicola M. Parry, DVM From August 25 to 27, 2016, the 7th International Association for the Study of Lung Cancer (IASLC) Latin American Lung Cancer Conference will take place […] Read more
New oncology drugs have, for decades, followed a well-trodden path of sequential clinical trials to get from the laboratory to the patient. This model has proven its worth by delivering […] Read more
Tobacco smoking dramatically increases the risk of developing lung cancers, and it has long been recognized that nicotine addiction is one of the biggest obstacles to changing current smokers’ behavior. […] Read more
By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) […] Read more
The International Association for the Study of Lung Cancer (IASLC) and the Oncology Unit of the 3rd Department of Medicine, Medical School of Athens, “Sotiria” Hospital, Greece organized and hosted […] Read more
By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung […] Read more